Preparation and quantification of pseudotyped retroviral vector

Area of Science:

• Molecular Biology
• Gene Therapy
• Virology

Background:

• Retroviral vectors are crucial for gene therapy research due to high transduction efficiency.
• Cellular receptors and viral envelope proteins restrict target cell susceptibility to retroviruses.
• Murine leukemia retrovirus (MuLV) pseudotyped with vesicular stomatitis virus G glycoprotein (VSV-G) overcomes species barriers and enhances stability.

Purpose of the Study:

• To establish a method for preparing VSV-G pseudotyped MuLV retroviral vectors.
• To provide protocols for quantifying the transduction potency of these pseudotyped vectors.
• To enable high-transduction retroviral vector preparation for diverse target cells.

Main Methods:

• Transfection of 293T cells expressing Gag, Pol, and VSV-G (293 GPG cell line) with a retroviral vector plasmid.
• Preparation of VSV-G pseudotyped MuLV retroviral supernatant.
• Quantification of transduction potency using titration, electron microscopy (EM), and reverse transcriptase (RT) assay.

Main Results:

• Successful establishment of a 293 GPG cell line for producing VSV-G pseudotyped MuLV vectors.
• Demonstration of high transduction rates of the pseudotyped retroviral vectors across various cell types.
• Validated methods for accurate quantification of vector potency.

Conclusions:

• The developed protocols facilitate the preparation of highly efficient pseudotyped retroviral vectors.
• This method offers a robust approach for gene therapy applications requiring broad target cell transduction.
• VSV-G pseudotyped MuLV vectors represent a promising tool for advancing gene therapy research and clinical trials.